show episodes
 
P
Pharma Marketing Talk
Monthly
 
Interviews of leaders and innovators in pharmaceutical marketing.
 
Shanna Landolt, leading executive recruiter interviews top thought leaders from the pharmaceutical and biotechnology industry to share their expertise with the pharma and biotechnology community.
 
Here at Drug Discovery World (DDW) we've been publishing articles written by leading experts in the Drug Discovery, Pharmaceutical, and BioPharmaceutical industries for nearly 20 years. DDW has grown as a quarterly business review of drug discovery and development. However, we realised that for some, it might be easier to listen to our content on the go, so we've created this podcast to allow you to do just that. In our journal and this podcast, we cover topics surrounding: drug discovery; d ...
 
W
What The Pharma
Monthly+
 
Answering questions around the pharmaceutical & biotechnology industry through podcast and social media
 
P
Pharma Talk
Weekly
 
Pharmaguy (aka John Mack) is a thought leader in pharmaceutical marketing with more than 30 years experience in the digital space, including interactive game design, computer-based learning, drug website development, ehealth ethics, and social media.
 
Good Pharma Manufacturing covers many pharmaceutical topics from cGMP's, GDP's, compliance, training, drug recalls, 483's, the history of the pharmaceutical industry, management, case studies and more.
 
In this audio program, you meet movers, shakers and innovators in the eyeforpharma network who transform the pharmaceutical sector. Our mission is to make pharma more open and valued. We’re creating a movement for industry leaders who prioritize value for patients and healthcare. To get involved in one of our programs and to discover many other valuable resources, join us via social.eyeforpharma.com or get in touch directly at podcast.us@eyeforpharma.com. Thanks for tuning in!
 
Podcast series featuring interviews with industry experts and thought leaders on topics related to Commercial Excellence in Pharma. For more information about Valeocon, visit www.valeocon.com.
 
Just about me and may everyday life.
 
Probology is an educational medical channel, that will help you ace your way throughout medical school.
 
F
FARM over PHARMA
Daily+
 
 
Loading …
show series
 
Semantic technologies - based on advanced statistics, data mining, machine learning and knowledge management - have existed for years, but are gaining much more momentum dealing with the growing need for efficient information management (IM). Better application of semantic technologies in linked data combined with the urgent need for better dat ...…
 
Adoption of a scientific informatics system is essential to the success of every drug discovery organisation. This episode discusses how we can drive strategic improvements in biologics drug discovery using scientific informatics. Good decisions can accelerate innovation and success, whereas poor decisions can hamstring a company for many years ...…
 
RNA-seq has revolutionised how scientists can interrogate gene expression. But after years of performing RNA-seq studies with short-read sequencers, many have realised that there is more to be discovered. Comprehensive transcriptome analysis – an essential tool for characterising disease, studying cell lines and measuring drug response – requir ...…
 
The Pistoia Alliance (whose membership includes most of the world’s major pharmaceutical companies, technology vendors and publishers active in the life science R&D sector), is keenly interested in discovering the ways in which innovation through pre-competitive collaboration can be used to explore and exploit the constant stream of new technol ...…
 
Technologies have been honed to overcome many of the challenges of administering peptide therapeutics orally, but obstacles remain before drug developers can fully realise the vast potential. Proteins and peptides are the building blocks of life and have evolved to become a very promising basis for targeting a range of diseases. Over the past 3 ...…
 
CRISPR-Cas9 has rapidly transformed our ability to perform targeted gene editing. While the technique has received much interest for its potential in the field of gene therapy, advances in its high-throughput use mean it can now open up a wealth of opportunities in drug discovery too. CRISPR-Cas9, short for clustered regularly interspaced short ...…
 
Valsartin API NDEA / NDMA contamination, MAPP 5014.1 Risk Based Site Selection Model. OSS 483 Inspection. Good Pharma Manufacturing covers many pharmaceutical topics from cGMP's, GDP's, compliance, training, drug recalls, 483's, the history of the pharmaceutical industry, management, case studies and more.…
 
A silo mentality is an issue for any organisation, but it is particularly problematic for the pharmaceutical industry. Drug development is a multidisciplinary endeavour that relies on the cumulative efforts of highly skilled teams in order to be successful. Yet these teams cannot work in isolation. Few development challenges reside within their ...…
 
The first results for the Reproducibility Project: Cancer Biology offer insights into the time and cost of conducting replication studies in preclinical cancer biology. While many agree that developing a therapeutic should not be pursued unless grounded in reproducible preclinical results, the costs of replication have, to date, not been consid ...…
 
Optimizing the receptor binding kinetics of new drugs can have significant benefits, ranging from improved duration of action to enhanced efficacy through the insurmountable antagonism of dynamic physiological systems. Despite this, the kinetics of new receptor ligands are rarely measured early in the drug discovery process, largely because cur ...…
 
In our latest podcast, KP Jimmink, a senior marketing executive with more than 25 years’ experience in life sciences and other industries, talks about his lessons learned from helping companies embark on and succeed in digital business transformation efforts.
 
The human kinome comprises 518 known protein kinases and more than 20 lipid kinases. Nearly all aspects of control within a cell are modulated by reversible phosphorylation of proteins, mediated by protein kinases. Abnormal phosphorylation is a cause or effect of many diseases including cancer and inflammatory diseases, hence many pharma and bi ...…
 
Good Pharma Manufacturing covers many pharmaceutical topics from cGMP's, GDP's, compliance, training, drug recalls, 483's, the history of the pharmaceutical industry, management, case studies and more.
 
Smac mimetics are a new class of targeted drugs being developed for the treatment of solid tumours and hematologic cancers. Smac mimetics specifically induce apoptotic cancer cell death and block pro-survival signalling in cancer cells. This episode provides an overview of the biology of Smac, an endogenous pro-apoptotic molecule, and the devel ...…
 
Listen to our recent podcast where we talk to Geoff Zassenhaus about his lessons learned from establishing a Continuous Improvement culture at Novartis US Sales Operations.
 
In our interview with Chris Gish, an experienced commercial leader with 25 years of experience in the pharmaceutical industry, we explore the importance of rep engagement and a supportive operational culture to execute selling strategies effectively, and the need to align customer touch points across the organization.…
 
This episode summarises some of the technical and regulatory challenges posed by next-generation sequencing technologies and the efforts being made to address them. Next-Generation Sequencing is moving quickly from early research into the regulated domains of drug development, diagnostic development, and clinical decision-making. Next-generatio ...…
 
This episode discusses issues around artificial intelligence & Biopharma R&D IT, and outlines how AI can be a potentially transformative technology for the biopharmaceutical and healthcare industries. "...R&D productivity remains an ongoing concern. Artificial Intelligence and the accompanying analytics are now so advanced that these tools prom ...…
 
Flow cytometry is a powerful tool for cell quantitation and analysis across a wide range of clinical and research applications. Most commonly used in the fields of immunology and haematology, recent improvements in instrument automation and throughput mean that the technique is now emerging as an increasingly attractive high-throughput screenin ...…
 
Increasing clinical success by implementing improved methodologies in early phase drug discovery. Using primary cells and 3D culture models to enhance cancer drug discovery. The high stakes of drug discovery and development lead pharmaceutical companies to be meticulous in ensuring a target is validated and that compounds are effective against ...…
 
Welcome to this bonus episode of the Drug Discovery Podcast. Today’s episode is an hour long episode taken from one of our DDW Webinars. Kinases are one of the most widely-studied drug target classes, with over 20 years in the spotlight for drug discovery research. Selecting optimized assays for screening, hit validation, selectivity profiling, ...…
 
The current environment for early-stage drug discovery and development is fluid and the probability of success continues to be challenging. Advancing an idea from an academic or basic research setting into a therapeutic product that benefits patients is time- and capital-intensive, sometimes inefficient and – frustratingly often – unsuccessful. ...…
 
Identifying functional molecules with the potential to be developed into new therapeutics is often the sole aim of phenotypic drug discovery. However, the approach also provides valuable opportunities to uncover previously unknown, disease-specific drug receptors that can then be exploited through target driven means. Although target deconvolut ...…
 
With the rapid generation of biological screening data and the potential for innovative selection of compounds for screening, the importance of multivendor collaborations together with improvements in automation has never been greater in terms of helping the drug discovery community as a whole. The creation and subsequent development of inhaled ...…
 
The hepatitis B crisis is a worldwide unmet medical need. Hepatitis B (HBV) is the cause of a silent epidemic that has resulted in a worldwide healthcare crisis. Despite the significant burden it places on communities across the globe, hepatitis had been mainly ignored as a health and clinical development priority until recently. Hepatitis B in ...…
 
Dr. Gunjan Bhardwaj, Co-Founder & Chief Executive of Innoplexus speaks with Shanna Landolt about how AI and Big Data is transforming the future of healthcare.
 
For many years we have used the term bioinformatics to describe, well, anything outside cheminformatics in the R&D informatics domain. It has been a ‘catch-all’ term to label informatics tools that handle biologically relevant information. But the tools and software that have been labelled as such have not been expansive – albeit they are biolo ...…
 
Inbred mice are critical tools in biomedical research and one particular strain, known as C57BL/6 (Black 6 or B6, for short), is rapidly becoming the standard model for many applications and revolutionising modern research. Understanding the B6 mouse, its origins, characteristics and potential is required to make full and appropriate use of thi ...…
 
Drug discovery is undergoing a transformation powered by advances that magnitude more molecules and enable smarter selection of compounds. We are on the cusp of having previously unimaginable amounts of information about each target and many more targets to prosecute. Thanks to more frequent co-operative hit discovery programmes, the need for i ...…
 
Chris Sellin, Head of US Operational Excellence & Analytics at Shire, shares his insights on how analytics in pharma has evolved and how a strong analytics foundation plays a key role in driving commercial impact.
 
In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment. With budgets being tight and time scarce, outsourcing has become more com ...…
 
In this episode, we talk to Jeff Schnack of 3Rock Consulting about the pharmaceutical commercial model in Japan and how it is evolving given emerging regulations and market changes.
 
The use of robots to automate high-volume repetitive tasks has been common practice going back to the early 1970s. Recent advances in robot technology are going to change the breadth of applications suitable for robots and alter how we think about robotic integration. For researchers in the drug discovery and development space, these advancemen ...…
 
Therapeutic antibodies are the fastest growing class of drugs, with continuous increases in the number of innovator and biosimilar drugs in development. Drug development and clinical trials necessitate the ability to specifically, sensitively and reproducibly measure the concentration and bioavailability of these drugs in pharmacokinetic assays ...…
 
Heterocycles are key structural components of many of the anti-cancer drugs available on the market today. Indeed, of the novel molecular anti-cancer agents approved by the FDA between 2010 and 2015, almost two-thirds contained heterocyclic rings within their structures. In this episode, we look at some of the most important heterocyclic compou ...…
 
Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond to these drugs is challenging, in large part because good predictive biomarkers have yet to be identified and validated. Understanding the r ...…
 
In this episode, Jeff Hoover, Head of Global Commercial Learning at GE Healthcare, shares his insights on the changing role of the pharma sales force in an increasingly digital world.
 
This episode discusses how RNA interference and CRISPR/Cas9 technologies are helping to build better mouse models and push drug discovery into a new era. Most, if not all, consumers are feeling the weight of rising drug costs. But while much of the controversy surrounding rising drug prices has focused on a handful of pharmaceutical companies t ...…
 
In this episode, we talk to Kristi Onkka, a healthcare marketing expert, about the applications of augmented reality and virtual reality (AR/VR) technology in healthcare.
 
Phenotypic screening is transforming drug discovery as advances are made in development of human-based physiologically-relevant in vitro systems. Integration of phenotypic drug discovery approaches with target-based screening can improve success rates as assays can be leveraged for the discovery of novel mechanisms and for building knowledge of ...…
 
Using scientific software can be frustrating and time-consuming, resulting in less productive research. This episode aims to demonstrate that User Experience (UX) Design – an evidence-based design process that centres on the behaviours and needs of users – offers specific efficiency benefits for life science R&D. Already well-established in oth ...…
 
Everything in its place and weekly 483 Good Pharma Manufacturing covers many topics from cGMP's, GDP's, compliance, training, drug recalls, 483's, the history of the pharmaceutical industry, management, case studies and more.
 
In our conversation with Don Apruzzese, an expert in consumer marketing and currently Managing Partner at The Novita Group, we explore how to optimize the customer experience in healthcare using innovative approaches and technologies, to drive better patient outcomes.
 
There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture. Scaffold-free 3D culture systems that generate spheroids (and other similar multicellular aggregations) have proved useful as they offer an easy route to access 3D culture and transition into plate-based h ...…
 
Human errors in the work place cause many issues. Here is my top 10 list of causes. Good Pharma Manufacturing covers many topics from cGMP's, GDP's, compliance, training, drug recalls, 483's, the history of the pharmaceutical industry, management, the fda, case studies and more.
 
Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and fast. What is needed is not just new assays, technology and ideas. It is new organisations, influencers and shared working. A generation Y approach ...…
 
In this discussion with John Glasspool, a recognized thought leader on patient access and an experienced commercial leader who served in senior roles at Baxalta, Baxter, Novartis and Janssen, we explore the implications of the inevitable shift from price to value.
 
In our conversation with Bill Fleming, who has been consulting to commercial pharma organizations for over 30 years, we explore what it takes to build multi-channel marketing capabilities.
 
In this episode, we talk to Eva Walde, VP Commercial Operations International Region at Thermofisher, about the international aspects of commercial and how to implement global marketing efforts that recognize, and can be adapted to, local market needs.
 
Google login Twitter login Classic login